Search
Now showing items 1-5 of 5
Drug Discovery against Acanthamoeba Infections: Present Knowledge and Unmet Needs
(MDPI, 2020)
Although major strides have been made in developing and testing various anti-acanthamoebic drugs, recurrent infections, inadequate treatment outcomes, health complications, and side effects associated with the use of ...
Whole Organism Model to Study Molecular Mechanisms of Differentiation and Dedifferentiation
(MDPI, 2020)
Cancer recurrence has remained a significant challenge, despite advances in therapeutic approaches. In part, this is due to our incomplete understanding of the biology of cancer stem cells and the underlying molecular ...
Metronidazole conjugated magnetic nanoparticles loaded with amphotericin B exhibited potent effects against pathogenic Acanthamoeba castellanii belonging to the T4 genotype
(Springer, 2020)
Acanthamoeba castellanii can cause granulomatous amoebic encephalitis and Acanthamoeba keratitis. Currently, no single drug has been developed to effectively treat infections caused by Acanthamoeba. Recent studies have ...
Antiamoebic activity of plant‑based natural products and their conjugated silver nanoparticles against Acanthamoeba castellanii (ATCC 50492)
(Springer, 2020)
Acanthamoeba spp. are the causative agent of Acanthamoeba keratitis and granulomatous amoebic encephalitis (GAE). The current options to treat Acanthamoeba infections have limited success. Silver nanoparticles show ...
HBN Nanoparticle-Assisted Rapid Thermal Cycling for the Detection of Acanthamoeba
(MDPI, 2020)
Acanthamoeba are widely distributed in the environment and are known to cause blinding keratitis and brain infections with greater than 90% mortality rate. Currently, polymerase chain reaction (PCR) is a highly sensitive ...